Drugs / calcipotriene/betamethasone dipropionate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03308799 | Oct 2017 → Jun 2018 | psoriasis | MC2 Therapeutics | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-08-21 | MC2 Therapeutics | Results MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis mc2therapeutics.com ↗ |
| 2015-05-01 | MC2 Therapeutics | Results MC2 Biotek successfully completes plaque psoriasis study mc2therapeutics.com ↗
MC2 Biotek has received positive results from a plaque psoriasis study comparing MC2-01 PAD™ Cream (fixed dose combination of Betamethasone dipropionate/calcipotriene) to vehicle, monads, Taclonex Ointment and Taclonex Topical Suspension. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | MC2 Therapeutics | Huadong Medicine reports positive Phase 3 topline results for Wynzora® (MC2-01) cream in China mc2therapeutics.com ↗ |
| 2019-08-07 | MC2 Therapeutics | MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients with Plaque Psoriasis Treated with MC2-01 PAD TM Cream mc2therapeutics.com ↗ |
| 2018-08-21 | MC2 Therapeutics | MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis mc2therapeutics.com ↗ |
| 2015-05-01 | MC2 Therapeutics | MC2 Biotek successfully completes plaque psoriasis study mc2therapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcipotriene/betamethasone dipropionate | “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream” NCT03308799 ↗ |
| Known as | MC2-01 | “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream” NCT03308799 ↗ |
| Action | Inhibit | “CAL/BDP has shown an inhibitory effect on key pathogenic cytokines in psoriasis including tumor necrosis factor-α, interleukin (IL)-17, and IL-23.” PMID 37490268 ↗ Jul 2023 |